Indication: Metastatic Esophageal Carcinoma
A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) + Lenvatinib (E7080/MK-7902) + Chemotherapy Compared with Standard of Care as First-line Intervention in Participants with Metastatic Esophageal Carcinoma
Sub-indication: Gastrointestinal Cancer
Study Type: Drug Study
Principal Investigator: Michael Driscoll, M.D.Norton Cancer Institute
Sponsor: Sponsor: Merck Sharp & Dohme CORP